Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
127.64
-0.20 (-0.16%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Ascendis Pharma Balance Sheet

Millions EUR. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2012
Cash & Equivalents
392.16444.77446.27584.52598.11
Upgrade
Short-Term Investments
7.28290.69235.8134.280
Upgrade
Cash & Cash Equivalents
399.44735.46682.06718.8598.11
Upgrade
Cash Growth
-45.69%7.83%-5.11%20.18%115.25%
Upgrade
Receivables
57.126.6624.18.726.88
Upgrade
Inventory
208.93130.6775.4100
Upgrade
Other Current Assets
37.2530.6824.3212.626.19
Upgrade
Total Current Assets
702.72923.47805.89740.13611.17
Upgrade
Property, Plant & Equipment
110.63129.1126.05108.1145.07
Upgrade
Long-Term Investments
5.6930.42145.91124.4615.54
Upgrade
Goodwill and Intangibles
4.424.835.275.723.5
Upgrade
Other Long-Term Assets
2.131.921.811.381.46
Upgrade
Total Long-Term Assets
122.87166.27279.04239.6665.57
Upgrade
Total Assets
825.591,0901,085979.79676.73
Upgrade
Accounts Payable
94.57101.0359.4221.927.77
Upgrade
Deferred Revenue
7.1314.215.570.360.86
Upgrade
Current Debt
025.4276.865.9
Upgrade
Other Current Liabilities
634.8130.6128.3823.6913.47
Upgrade
Total Current Liabilities
736.51171.27100.3652.847.99
Upgrade
Long-Term Debt
644.27482.9697.9785.1230.72
Upgrade
Other Long-Term Liabilities
-409.49172.162.963.160.91
Upgrade
Total Long-Term Liabilities
234.78655.12100.9388.2831.63
Upgrade
Total Liabilities
971.28826.39201.29141.0879.62
Upgrade
Total Debt
644.27508.38104.9691.9836.62
Upgrade
Debt Growth
26.73%384.35%14.12%151.17%-
Upgrade
Retained Earnings
-153.45255.67875.99831.49590.67
Upgrade
Shareholders' Equity
-145.7263.35883.64838.71597.11
Upgrade
Net Cash / Debt
-244.83227.08577.1626.82561.49
Upgrade
Net Cash / Debt Growth
--60.65%-7.93%11.64%102.07%
Upgrade
Net Cash Per Share
-4.354.0510.5412.3812.07
Upgrade
Working Capital
-33.79752.2705.53687.33563.18
Upgrade
Book Value Per Share
-2.594.7016.1316.5712.84
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).